About Us

Founded in 2017 by Dr. Xiaodong Wang and Dr. Zhiyuan Zhang, Sironax has built a diverse pipeline of programs by targeting contributors of aging, degeneration, metabolic dysfunction, and inflammation. We are conducting clinical studies with SARM1 inhibitor SIR2501, NAMPT activator SIR4156, and RIPK1 inhibitor SIR9900, in addition to our ongoing preclinical research.

With operations in the United States, China, Switzerland, and Australia, Sironax has a growing global team of more than 170 employees. Our team, with decades of global pharmaceutical R&D experience, shares a vision of shifting the treatment paradigm to ultimately improve the lives of millions of patients worldwide.